The landscape of treating metastatic prostate cancer has evolved with the addition of Androgen Receptor pathway inhibitor (ARPI) to Androgen Deprivation Therapy (ADT), significantly improving survival rates. However, prolonged use of these therapies introduces notable side effects, prompting a need to revisit intermittent treatment duration. The EORTC 2238 De-Escalate trial is a pragmatic trial seeking to reassess the role of intermittent therapy in patients undergoing maximal androgen blockade (MAB) for metastatic hormone naïve prostate cancer (mHNPC), i.e., the combination of ADT with an ARPI, with the aims of reducing side effects, enhancing Quality of Life (QoL) and optimizing resource usage, while maintaining oncological benefits.
Frontiers in oncology. 2024 May 08*** epublish ***
Guillaume Grisay, Fabio Turco, Saskia Litiere, Béatrice Fournier, Anna Patrikidou, Enrique Gallardo, Ray McDermott, Ahu Alanya, Silke Gillessen, Bertrand Tombal
Department of Medical Oncology, Centres Hospitaliers Universitaires HELORA, La Louvière, Belgium., Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland., Statistics Department, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium., Medical Department, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium., Genito-Urinary Oncology Group and Early Drug Development (DITEP), Gustave Roussy, Villejuif, France., Department of Oncology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain., Department of Medical Oncology, St Vincents University Hospital and Cancer Trials, Dublin, Ireland., Quality of Life Department, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium., Division of Urology, Cliniques Universitaires Saint Luc, Brussels, Belgium.